Sarcoglycanopathies are a genetically heterogeneous group of autosomal recessive muscular dystrophies in which the primary defect may reside in any of the genes coding for the different partners of the sarcolemmal sarcoglycan (SG) complex: the a-SG (LGMD2D at 17q21.2), the P-SG (LGMD2E at 4q12), the y-SG (LGMD2C at 13q12), and the 6-SG (LGMD2F at 5q33). We report a series of 20 new unrelated families with 14 different mutations in the a-SG gene. Along with the mutations that we previously reported this brings our cohort of patients with a-sarcoglycanopathy to a total of 31 unrelated patients, carrying 25 different mutations. The missense mutations reside in the extracellular domain of the protein.
is the 50 kDa component of the dystrophin connected sarcolemmal sarcoglycan (SG) ~o m p l e x .~ This protein has been shown to be deficient in severe childhood autosomal recessive muscular dystrophy (SCARMD),i' a Duchenne-like disease affecting both males and females, which sometimes overlaps clinically with the less severe limb-girdle muscular dystrophy (LGMD).7 Alpha-sarcoglycan deficiency is genetically heterogeneous.' It may result from primary defects in the a-sarcoglycan gene itself (LGMD2D at 17q2 1 .2)1°-'' or be secondary to defects involving other S G genes: 0-SG at LGMD2E (4q1 2),13 l 4 y-SG at LGMD2C (1 3q1 2),15 and 6-SG at LGMD2F (5q33). 16 Several different mutations in the a-SG gene have already been reported by us1" and ~t h e r s l~-'~ in geographically widespread families. In this study we report an additional series of 20 unrelated LGMD families with primary a-sarcoglycanopathy (LGMD2D), carrying 12 novel mutations in the a-SG gene. From our cumulative collection of 25 different mutations in the a-SG gene, it now appears that (I) there are preferential sites (exon 3 ) and types (R77C, R284C) of mutations; (2) the 15 different missense mutations, exclusively located in the extracellular domain of the protein, result in variable decrease of the protein without drastically affecting the level of transcripts; (3) the severity of disease may be at least in part correlated with the genotype; and (4) there is no geographical restriction of LGMD2D.
Patients and methods

SUBJECTS AND CLINICAL STUDIES
Peripheral blood samples were obtained from patients and relatives in 51 unrelated families in which a-sarcoglycan deficiency had been ascertained by immunofluorescence or western blotting or both." All patients but patients 6571 and 6710 presented with a limb-girdle muscular dystrophy phenotype of variable severity. Noteworthy are the absence of heart involvement and mental retardation. The full clinical presentation of patients with a mutated a-sarcoglycan gene in 15 families is given in Eymard et ~1 . '~ Patient 6571, a female of French ancestry, was born in 1940 to unrelated parents. At the age of 54 she underwent a muscle biopsy to elucidate recurrent myositis-like episodes with raised serum creatine kinase activity. She complained of weakness but without a real impact on her physical activity. No muscle deficit was observed. Muscle biopsy showed unobtrusive muscular dystrophy alterations and a-sarcoglycan reduction.
Patient 6710, a female born in 1968 to related parents of North African origin, was found at the age of 24 to have a raised serum transaminase level during a routine occupational medicine check up. She complained of some tiredness in her professional activity (office worker) but was found to be normal on clinical examination by an experienced neurologist. Since serum creatine kinase was found to be repeatedly raised (700-2000 IU), a muscle biopsy was performed, showing limited muscular dystrophy alterations and marked a-sarcoglycan reduction. Total RNA was extracted from muscle biopsy specimens by RNAzol0(Bioprobe) according to the manufacturer's protocol. RT-PCR was performed on 4 pg of total RNA from muscle generating three overlapping fragments of a-sarcoglycan cDNA: fragment 1: 5' CCGTGTCTTTGTGCA-CACCTTGGA 3' and 5' CAAGGCTGA-GAGGAAGCGGCTGGCA 3'; fragment 2: 5' CCGCTTCCTCTCAG-CCTTGG 3' and 5' GGGAGGCAGCCGCT-CACCTGTG 3'; fragment 3: 5' AACACAGAGGAGCT-GCGG 3' and 5' TGTGGACAGAGAAG-GGAGGATG 3'.
GAPDH mRNA was coamplified as an internal control in quantitative RT-PCR (5' GGGAGATTCAGTGTGGTGGG 3' and 5' CGGGGCTCTCCAGAACATCA 3'). PCR conditions were as follows: hot start after five minutes at 80°C, 60°C for one minute, and 45 Table 3 The cumulative spectrum of missense mutations in the a-sarcoglycan gene missense mutations of which two (R34H and R77C) had already been described in our previous report." In this series, 26 of the 40 mutated chromosomes carried a missense mutation observed more than once in unrelated families. None of these mutations was found in 200 control chromosomes. In tables 2 and 3 and in fig 1 we give a cumulative tabulation of the 25 different mutations in the a-SG gene that we have observed to date, including the 13 that we previously reported." In this tabulation the mutations are s~l i t into two cat- tha; the first 'one is similar to that already reported by McNally et ~1 . '~ It is still in frame and corresponds to the splicing of exons 6 and 7 (not shown). The second one is out of frame because it corresponds to the skipping of the 155 bp long exon 3 (not shown). RT-PCR from patients showed the three a-SG transcript forms at normal or slightly reduced levels, except for subjects carrying a homozygous splicing mutation (patients 6141 and 6280, see discussion). seconds at 72"C, 45 seconds at 94"C, 45 seconds at 60°C for 35 cycles, with a final elongation for two minutes at 72°C. Transcripts with abnormal size were purified from the gel and sequenced using the same PCR primers.
PROTEINS
Analysis by IF and western blotting of the aand y-SG proteins in patient muscle specimens showed a significant decrease, of variable degrees from patient to patient, but the decrease of a-SG was consistently more pronounced (tables 5 and 6). Results
MUTATIONS
The first eight exons of the a-SG gene and Discussion
In a previous study we had analysed 13 independent patients with normal dystrophin and deficient adhalin (now a-SG). In this first series, 11 cases were classified as primary adhalinopathies because the a-SG gene itself was mutated, with altogether five different null and eight different missense mutations. l 1 In the present series we investigated 51 new families out of which 20 families were found to harbour mutations in the a-SG gene, with 12 additional novel mutations (five null and seven missense) \ (~b l e s 2 and 3). It has now become possible to have a broad view of the molecular pathology of the a-SG gene and its consequences. their flanking intronic sequences were scanned by DGGE analysis in 51 unrelated families with male and female LGMD patients with a-sarcoglycan deficiency and normal or near normal dystrophin levels. We found the a-sarcoglycan gene mutated in 20 families of widespread geographical origin (France, UK, Italy, Germany, Spain, North Africa, USA). Nine unrelated patients were homozygous and 11 were compound heterozygotes. In all compound heterozygotes but one, both mutations were identified. A total of 14 different mutations were observed: five novel null mutations (nonsense, frameshift, or splice) and nine
Null EXONS Missense mutations mutations
patients selected on the following criteria: (1) proximal muscle dystrophy of variable severity, (2) normal dystrophin, and (3) absence or reduced amount of a-sarcoglycan. Although this high proportion of patients with a primary defect of the a-SG may be partly attributed to the efficiency of the screening method used (DGGE of genomic DNA exploring 90% of the coding sequence + flanking intronic regions), it may also reflect a sampling bias since we serve as a reference laboratory for sarcoglycanopathies.
Another important feature is the variety of different mutations; altogether we observed 25 (table 2) is unauestionable. We believe that the 15 different missense mutations are also pathogenic because (1) they cosegregated in each family with the disease trait, (2) they affected conserved residues,' and (3) they were not found on 200 control chromosomes. Very few neutral sequence variations that can be considered as polymorphisms were found (described in the Results section). The considerable allelic heterogeneity and the wide geographical distribution of the patients carrying different haplotypes indicate that the disease results from independent mutations occurring in different populations (21 from western Europe, four from USA, six from North Africa). This is substantiated by the other cases reported in Brazil,19 USA," and Japan.'' This high allelic diversity was also found in the endogamic populations of North Africa (Algeria, Morocco), where in six unrelated families the patients were homozygous for six different mutations in the a-SG gene. This indicates that in North Africa sarcoglycanopa- thies are genetically heterogeneous, and hot solely the result of defects in the y-SG gene,15 as suggested by previous linkage In non-endogamic western countries, 72% of the patients were compound heterozygotes. In the remaining proportion of 28% of homozygotes there was no known consanguinity. In our computation of the frequency of recurrent mutations, however, we considered the latter to be carried by two identical chromosomes derived from a founding ancestor (table 4) .
Regarding the site of the mutations on the 
0IF
affected chromosomes. However, the most salient finding is that some of the missense mutations recur with a striking frequency (table 4). Because they were found in subjects from various ethnic backgrounds and with different haplotypes (data not shown) they must result from independent events. The R77C -nd: not done.
: by western blot (normal signal = +++). IF : by irnmunofluorescence (normal signal = +++).
mutation is by far the most frequent mutation, accounting for 32% of the mutated chromosomes. Four out of these five recurrent mutations occur at CpG sites, involving codons 34, 77, 98, and 284 (table 4). CpG sites are generally considered as the target of about one third of mutations found in human genetic diseases and turn our^.^^ Interestingly, out of the In the first place it is clear that among dystrophin normalla-SG deficient patients, LGMD2D is not a rare condition. Our cohort of 31 independent families was obtained by systematic analysis of a series of 64 unrelated 151 CpG sites present in the portion of the a-SG gene that we explored by DGGE, 50 lie in the coding region, and only four were mutated. This preference is still unexplained. It is tempting to consider it to be a result of preferential methylation, as recently d i s c u s~e d .~~ This hypothesis was ruled out at least in the case of somatic mutations of ~5 3 . '~ In our series, one in two patients (1 5/31) carried, at least on one chromosome, the C G C j T G C mutation in codon 77 (tables 3 and 4). This is reminiscent of other highly recurrent mutations at preferential CpG sites, such as in the factor IX30 and the p cardiac myosin heavy chain genes." The only recurrent point mutation of our series that did not occur at a CpG is V247M (table 5) , reminiscent of a similar G T G j A T G (V162M) observed in the factor VIII gene in 11 cases of haemophilia A." It is puzzling that 11 out of 13 bases around this mutated site in the factor VIII gene and in the a-SG gene are identical. A practical consequence of the recurrence of some mutations is the possibility of screening a large number of probands by comparison with previously identified DGGE patterns and to check each suspected mutation by restriction enzyme digestion or sequencing (table 3) . The gene products, transcripts, and protein were analysed, when possible, to see the molecular impact of each mutation. The mRNA level and size were normal, except in two patients harbouring splice mutations. In patient 6280 with a mutation in the donor site of exon 1, the transcript was aberrant; in patient 6141 with a mutation in the acceptor site of exon 6, the transcript was aberrant because of the splicing of exon 5 to a cryptic acceptor site in intron 6, resulting in a frameshift after exon 5.
As expected in null mutations the protein was not seen (table 5) . It is remarkable that, with the exception of R284C, every missense mutation results in a drastic decrease of the protein. The effect of missense mutations on the protein level is most probably posttranslational and not explained by an impact upon transcription, because whenever the transcript was studied (five cases) it was not found to be significantly decreased (table 6) . Three substitutions, V175A and the neighbouring L173P in exon 5, and V247M in exon 6 (fig I) , reside precisely within a potential glycosylation site.' Their possible impact on glycosylation was not tested. Missense mutations may also jeopardise the intrinsic stability of the a-sarcoglycan, and in turn destabilise the whole sarcoglycan complex." Indeed all the missense mutations reside in the extracellular domain and have a drastic quantitative effect on the protein level, suggesting that the mutated regions are critical in the formation and stability of the sarcoglycan complex. Another possibility is that the observed missense mutations perturb those epitopes that are recognised by the antibodies used in this study, thus giving a false idea of the amount of protein. It should be noted that the complete absence of a-SG, which is invariably associated with a severe phenotype, is accompanied either by a drastic decrease of y-SG (case 6520, table 5) or by a moderate decrease of y-SG (case 6141, table 5). Patient 6520 is homozygous for the R77C missense mutation, whereas patient 6141 is homozygous for a null mutation. This suggests that a mutated a-SG may be more deleterious to the whole complex stability than its total absence. The missense mutations observed designate candidate residues essential for the formation and stability of the complex.
The clinical presentation of 3 1 patients with 25 different mutations in the a-SG gene is far from being unequivocal. The phenotypes of 15 of them are fully described by Eymard et ~1 . '~ The problem is further complicated by the fact that affected sibs in the same family may have a different clinical c~u r s e .~
To obtain a contrasting view of the clinical course we have classified the phenotypes in four simplistic but operational categories: severe for Duchenne-like (onset around age 5), intermediate for Beckerlike (onset at the age of 10-15), moderate for adult onset with disability, and benign for adult onset without disability (tables 5 and 6).
A first conclusion is that, without exception, homozygous null mutations are responsible for a severe phenotype (table 5). In two cases (table 6) a null mutation was combined with a R77C missense on the other chromosome, giving rise to an early onset disease of variable severity (Duchenne-like in patient 6379, and Becker-like in patient 6620) (table 6). For missense mutations, correlations mav be examined in homozygotes (table 5) and in compound heterozygotes bearing the same combination of alleles (table 6). In table 5 where 13 homozygous patients are classified according to the four phenotypic categories, eight cases carry a missense mutation. It appears that the R284C substitution results in a much less severe disease. The two homozygous female patients with this mutation, 57 and 29 years old respectively, only suffered from exercise intolerance (patients 6570 and 6571 described in Patients and methods section). They were biopsied on the discovery of high serum creatine kinase. Their a-SG was moderately decreased, with little secondary impact on y-SG (table 5) . The site of this substitution is very close to the transmembrane domain, but still on the extracellular side (fig l) , and may be less critical for the integrity of the complex. The R284C mutation might be the first example of a new category of functional mutants of a-SG with little or no quantitative effect.
The others, R34C, R34H, and R77C, are associated with a more severe disease with childhood onset. There is, however, one exception in patient 65 16 in whom homozygosity for R77C resulted in a less severe phenotype with adult onset. Other less severely affected R77C homozygous patients have been reported in Brazil. 19 For compound heterozygotes, we compared patients bearing a given allele combination (table 6). The two patients with the R34WR77C combination had a childhood onset, but they differ in the rate of progression. Two other patients with the R77CIR284C combination had different clinical courses, with childhood onset in one case and adult onset in the other (table 6) .
Altogether, with the exception of the always severe null mutations and the mild R284C allele, it does not seem possible to predict a specific phenotype from the type of mutation, especially for missense mutations, suggesting the role of epistatic factors. Further observations, with detailed study of the secondary effect of each mutation on the other members of the sarcoglycan complex and other more remote sarcolemmal proteins, are needed to shed more light on the pathophysiology of sarcoglycanopathies.
